ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

Panel Considers Easing Comp Center Independence Requirement, but Realizes It Lacks That Authority

February 18, 1977

NCABP “Anyone With Same Facts Would Have Come To Same Conclusion

October 28, 1994

Von Eschenbach Candidacy for FDA Hampered By Three Republican Holds.

December 1, 2006

Bevacizumab Prolongs Survival In Patients With Advanced Colorectal Cancer

November 26, 2004

Another Flat Budget For NIH And NCI Despite Strong Bipartisan Support.

January 11, 2008

House Appropriator Claims NCI, NLM Grants Funded Political Activity, Seeks OIG Probe

March 22, 2013